Relationship of soluble interleukin-2-receptor and interleukin-6 with class-specific rheumatoid factors during low-dose methotrexate treatment in rheumatoid arthritis

被引:0
作者
Spadaro, A
Taccari, E
Riccieri, V
Sensi, F
Scavalli, AS
Zoppini, A
机构
来源
REVUE DU RHUMATISME | 1997年 / 64卷 / 02期
关键词
interleukin-2; interleukin-6; rheumatoid factor; methotrexate; rheumatoid arthritis;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We studied the effect of a 6-month treatment with low-dose MTX in 22 RA patients, with the purpose of investigating the relationship of sIL-2R and IL-6 serum chancres with those of class specific RFs. The patients with RA had higher serum levels of sIL-2R (p<0.00001) and IL-6 (p<0.0005) than healthy volunteers. We found that the levels of IgM-RF (p<0.0004), IgA-RF (p<0.002), IgG-RF (p<0.025), sIL-2R (p<0.017) and IL-6 (p<0.044), as well as the main clinical and laboratory variables, were significantly reduced in RA patients treated with low dose MTX for six months. The changes from baseline of IgM-RF correlated with those of IL-6 (p<0.023), suggesting that MTX may affect IL-6 and IgM-RF production in part by a common mechanism. In conclusion our results show that there is a relationship between IL-6 and IgM-RF changes from baseline during MTX therapy, but the hypothesis of a link between the effects of this drug on cytokine network and RF production needs further investigation.
引用
收藏
页码:89 / 94
页数:6
相关论文
共 28 条
  • [1] ALARCON GS, 1990, ARTHRITIS RHEUM, V33, P1156
  • [2] CYTOKINES AND CYTOKINE INHIBITORS OR ANTAGONISTS IN RHEUMATOID-ARTHRITIS
    AREND, WP
    DAYER, JM
    [J]. ARTHRITIS AND RHEUMATISM, 1990, 33 (03): : 305 - 315
  • [3] AREND WP, 1993, TXB RHEUMATOLOGY, P227
  • [4] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS
    ARNETT, FC
    EDWORTHY, SM
    BLOCH, DA
    MCSHANE, DJ
    FRIES, JF
    COOPER, NS
    HEALEY, LA
    KAPLAN, SR
    LIANG, MH
    LUTHRA, HS
    MEDSGER, TA
    MITCHELL, DM
    NEUSTADT, DH
    PINALS, RS
    SCHALLER, JG
    SHARP, JT
    WILDER, RL
    HUNDER, GG
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (03): : 315 - 324
  • [5] CIRCULATING SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTORS, INTERLEUKIN-2 RECEPTORS, TUMOR-NECROSIS-FACTOR-ALPHA, AND INTERLEUKIN-6 LEVELS IN RHEUMATOID-ARTHRITIS - LONGITUDINAL EVALUATION DURING METHOTREXATE AND AZATHIOPRINE THERAPY
    BARRERA, P
    BOERBOOMS, AMT
    JANSSEN, EM
    SAUERWEIN, RW
    GALLATI, H
    MULDER, J
    DEBOO, T
    DEMACKER, PNM
    VANDEPUTTE, LBA
    VANDERMEER, JWM
    [J]. ARTHRITIS AND RHEUMATISM, 1993, 36 (08): : 1070 - 1079
  • [6] REGULATION OF INTERLEUKIN-6 RECEPTOR EXPRESSION IN HUMAN-MONOCYTES AND MONOCYTE-DERIVED MACROPHAGES - COMPARISON WITH THE EXPRESSION IN HUMAN HEPATOCYTES
    BAUER, J
    BAUER, TM
    KALB, T
    TAGA, T
    LENGYEL, G
    HIRANO, T
    KISHIMOTO, T
    ACS, G
    MAYER, L
    GEROK, W
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (05) : 1537 - 1549
  • [7] THE ROLE OF HUMAN INTERLEUKIN-6 IN B-CELL ISOTYPE REGULATION AND DIFFERENTIATION
    BERTOLINI, JN
    BENSON, EM
    [J]. CELLULAR IMMUNOLOGY, 1990, 125 (01) : 197 - 209
  • [8] BHARDWAJ N, 1989, J IMMUNOL, V143, P2153
  • [9] BROZIK M, 1992, J RHEUMATOL, V19, P63
  • [10] SOLUBLE INTERLEUKIN-2 RECEPTOR IN SERA AND SYNOVIAL-FLUIDS OF RHEUMATOID PATIENTS - CORRELATIONS WITH DISEASE-ACTIVITY
    CAROTTI, M
    SALAFFI, F
    FERRACCIOLI, GF
    BINCI, MC
    SARTINI, A
    CERVINI, C
    [J]. RHEUMATOLOGY INTERNATIONAL, 1994, 14 (02) : 47 - 52